Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-52058
Pharmacogenomics 2022 Aug 01;2313:739-748. doi: 10.2217/pgs-2022-0064.
Show Gene links Show Anatomy links

Pharmacogenetic testing-guided treatment for oncology: an overview of reviews.

de Lara DV , de Melo DO , Kawakami DY , Gonçalves TS , Santos PC .


???displayArticle.abstract???
Pharmacogenetics is the relationship between an individual's genetic variations and their response to pharmacological treatment. We conducted an overview of reviews on the use of post-treatment pharmacogenetic testing for oncology, based on clinically relevant gene-drug pairs. We conducted a search on Medline, Embase and Cochrane Library, from their inception to 18 June 2020. We selected six eligible systematic reviews. The most studied drug categories were estrogen agonists/antagonists and fluoropyrimidines associated with cytochrome P450 and dihydropyrimidine dehydrogenase genes (CYP2D6 and DPYD), but many studies were classified as being of critically low or low quality. There is a need for more high-quality primary studies and systematic reviews that assess the risk of bias, with consistent definitions of clinical outcomes to consider the benefits of pharmacogenetic testing for oncology.

???displayArticle.pubmedLink??? 36001087
???displayArticle.link??? Pharmacogenomics